Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients
Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC.
(WRAL Tech Wire)
Related: Campus Connections
Numbers show how Ireland was 'Much More Than a Game' for CarolinaUNC Football's victory over TCU may have been the centerpiece of a week in Ireland for the Aer Lingus College Football Classic, but Tar Heels...
Thu Sep 10, 2026There’s no fool like The Motley Fool
It all started April 1, 1994, with an internet message board post. "Joey Roman" bragged that a particular stock was "hotter than an egg on...
Wed Sep 9, 2026
The JB Cissell Memorial Fund
On September 7, 2019, Inside Carolina lost a treasured, founding member of its family in J.B. Cissell. You can read more about him and what...
Mon Sep 7, 2026
'Puppy Love': Dolly Parton's first recorded song, made at age 13, draws mourners to UNC
Flags across the state are flying at half-staff as fans mourn country music icon Dolly Parton. At UNC, her very first recorded song, cut when...
Sun Sep 6, 2026